A to Z / Metabolic / weight loss

Orforglipron

Also known as LY3502970.

Best known for The first once-daily oral non-peptide in the GLP-1 class

Evidence★★★★☆

Safety dataModerately characterised

Route Oral, once daily

United StatesFDA approved 1 April 2026 (Foundayo) for weight management

AustraliaNot approved

as at 16 September 2026

What it is

Orforglipron is an oral, non-peptide GLP-1 receptor agonist, approved in the United States on 1 April 2026 as Foundayo for long-term weight management.{{CITE:openfda-nda220934}} It is included here because it is central to the GLP-1 conversation and because the distinction matters: it is a small molecule, not a peptide, and that is what allows it to work as a daily tablet.

What the full entry covers

The book carries the rest of this entry:

Where the research stands, with every claim cited
What people commonly ask, and what the research shows so far
Dosing in four labelled bands, described and not recommended
Side effects, serious risks, cautions and interactions
Questions to discuss with your doctor
How it compares with Semaglutide, Oral GLP-1 Peptides, Tirzepatide, Retatrutide

Related entries

SemaglutideThe drug that changed obesity treatment · Evidence ★★★★★
Oral GLP-1 PeptidesThe answer to "can I take this without injecting?" · Evidence ★★★★☆
TirzepatideThe most effective approved weight-loss drug · Evidence ★★★★★
RetatrutideThe next-generation weight-loss drug that isn't approved yet · Evidence ★★☆☆☆

A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.

This page describes what is known and not known about Orforglipron. It is not medical advice and not a recommendation to use it.